Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 131

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Miller, Peter G., Sperling, Adam S., Brea, Elliott J., Leick, Mark B., Fell, Geoffrey G., Jan, Max, Gohil, Satyen H., Tai, Yu-Tzu, Munshi, Nikhil C., Wu, Catherine J., Neuberg, Donna S., Maus, Marcela V., Jacobson, Caron, Gibson, Christopher J., Ebert, Benjamin L.·2021·Blood Advances
DOI 10.1182/bloodadvances.2021004554
Open this paper in CoChat — free account

Abstract

Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is more common in patients exposed to cytotoxic therapies, has been shown to influence inflammatory immune programs, and is associated with an adverse prognosis in patients with NHL and MM receiving autologous transplantation. We therefore hypothesized that CHIP could influence clinical outcomes in patients receiving CAR T-cell therapy. In a cohort of 154 patients with NHL or MM receiving CAR T-cells, we found that CHIP was present in 48% of patients and associated with increased rates of complete response and cytokine release syndrome severity, but only in patients younger than age 60 years. Despite these differences, CHIP was not associated with a difference in progression-free or overall survival, regardless of age. Our data suggest that CHIP can influence CAR T-cell biology and clinical outcomes, but, in contrast to autologous transplantation, CHIP was not associated with worse survival and should not be a reason to exclude individuals from receiving this potentially life-prolonging treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2021004554

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Coombs, 2017, Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell., 21, 374, 10.1016/j.stem.2017.07.010 · DOI · Paper page
  2. Gibson, 2017, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J Clin Oncol., 35, 1598, 10.1200/JCO.2016.71.6712 · DOI · Paper page
  3. Mouhieddine, 2020, Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant, Nat Commun., 11, 2996, 10.1038/s41467-020-16805-5 · DOI
  4. Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
  5. Bick, 2020, Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis, Circulation., 141, 124, 10.1161/CIRCULATIONAHA.119.044362 · DOI · Paper page
  6. Miller, 2020, Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis, Blood., 136, 3051, 10.1182/blood.2020008206 · DOI
  7. Zebley, 2020, De novo DNA methylation programs regulate CAR T-cell exhaustion, J Immunol., 204, 246.5, 10.4049/jimmunol.204.Supp.246.5 · DOI
  8. Miller, 2020, Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade, JCO Precis Oncol., 4, PO.20.00186
  9. Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat Genet., 52, 1219, 10.1038/s41588-020-00710-0 · DOI · Paper page
  10. Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant., 25, 625, 10.1016/j.bbmt.2018.12.758 · DOI · Paper page
  11. Dong, 2014, The human SRCAP chromatin remodeling complex promotes DNA-end resection, Curr Biol., 24, 2097, 10.1016/j.cub.2014.07.081 · DOI
  12. Wong, 2018, Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential, Nat Commun., 9, 455, 10.1038/s41467-018-02858-0 · DOI
  13. Carty, 2018, The loss of TET2 promotes CD8+ T cell memory differentiation, J Immunol., 200, 82, 10.4049/jimmunol.1700559 · DOI · Paper page
  14. Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell., 170, 142, 10.1016/j.cell.2017.06.007 · DOI · Paper page

Cited by

See all 131

Metadata

Authors
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., Neuberg, D. S., Maus, M. V., Jacobson, C., Gibson, C. J., & Ebert, B. L.
Affiliations
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
  • Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA;
  • Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA;
ORCID
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2021-08-03
Volume
5
Issue
15
Pages
2982-2986
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2021004554
Cited by
131
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.